Review



chromium 51 51 cr release  (Revvity)


Bioz Verified Symbol Revvity is a verified supplier
Bioz Manufacturer Symbol Revvity manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 91
      Buy from Supplier

    Structured Review

    Revvity chromium 51 51 cr release
    Chromium 51 51 Cr Release, supplied by Revvity, used in various techniques. Bioz Stars score: 91/100, based on 4 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/chromium+51+51+cr+release/MicroBeta2+Microplate+Counters+for+Radiometric+and+Luminescence+Detection+with+6-detectors/pmc10663516-104-8-30
    Average 91 stars, based on 4 article reviews
    chromium 51 51 cr release - by Bioz Stars, 2026-09
    91/100 stars

    Images

    Related Articles

    Quantitation Assay:

    Article Title: Preclinical evidence for the effective use of TL-895, a highly selective and potent second-generation BTK inhibitor, for the treatment of B-cell malignancies
    Article Snippet: .. ADCC analysis was based on the quantitation of chromium-51 ( 51 Cr) release during lysis of target cells using luminescence detection on a MicroBeta2 2450-0060 liquid scintillation and luminescence counter (PerkinElmer, Waltham, MA, USA). .. All animal studies were conducted in compliance with the guidelines for the care and use of experimental animals and the studies were approved by the Institutional Animal Care and Use Committee (IACUC) of Crown Bioscience (Taicang, China), XenoSTART, EPO-GmbH, Shanghai ChemPartner Co., Ltd and EMD Serono Research and Development Institute following the guidance of the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC).

    Lysis:

    Article Title: Preclinical evidence for the effective use of TL-895, a highly selective and potent second-generation BTK inhibitor, for the treatment of B-cell malignancies
    Article Snippet: .. ADCC analysis was based on the quantitation of chromium-51 ( 51 Cr) release during lysis of target cells using luminescence detection on a MicroBeta2 2450-0060 liquid scintillation and luminescence counter (PerkinElmer, Waltham, MA, USA). .. All animal studies were conducted in compliance with the guidelines for the care and use of experimental animals and the studies were approved by the Institutional Animal Care and Use Committee (IACUC) of Crown Bioscience (Taicang, China), XenoSTART, EPO-GmbH, Shanghai ChemPartner Co., Ltd and EMD Serono Research and Development Institute following the guidance of the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC).



    Similar Products

    chromium cr 51 release cytotoxicity assay human cervical carcinoma cell line hela  (ATCC)
    99
    ATCC chromium cr 51 release cytotoxicity assay human cervical carcinoma cell line hela
    Chromium Cr 51 Release Cytotoxicity Assay Human Cervical Carcinoma Cell Line Hela, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/chromium+51+51+cr+release/HeLa/10__1182_slash_blood__v96__12__3827-68-0-12
    Average 99 stars, based on 1 article reviews
    chromium cr 51 release cytotoxicity assay human cervical carcinoma cell line hela - by Bioz Stars, 2026-09
    99/100 stars
    		  Buy from Supplier
    chromium-51 ( 51 cr) release assay  (HARTMANN ANALYTIC)
    90
    HARTMANN ANALYTIC chromium-51 ( 51 cr) release assay
    <t>Chromium</t> <t>51</t> release assay for the evaluation of cytotoxicity of BCMA.CAR-T cells. A BCMA + U266 cell line or a BCMA − HL60 cell line were incubated for 4 h. The curves depict the specific lysis of target cells by BCMA.CAR-T cells at different E/T ratios ranging from 30:1 to 1:1. There was no significant difference in lytic ability after 14/90 days or 1 year of cryopreservation ( F = 3.385, p = 0.125). Non-transduced T cells (NT) served as a negative control at an E/T ratio of 10:1.
    Chromium 51 ( 51 Cr) Release Assay, supplied by HARTMANN ANALYTIC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/chromium+51+51+cr+release/chromium+51+release+assay/pmc10855166-163-15-19
    Average 90 stars, based on 1 article reviews
    chromium-51 ( 51 cr) release assay - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    chromium-51 ( 51 cr) release method  (srl inc)
    90
    srl inc chromium-51 ( 51 cr) release method
    <t>Chromium</t> <t>51</t> release assay for the evaluation of cytotoxicity of BCMA.CAR-T cells. A BCMA + U266 cell line or a BCMA − HL60 cell line were incubated for 4 h. The curves depict the specific lysis of target cells by BCMA.CAR-T cells at different E/T ratios ranging from 30:1 to 1:1. There was no significant difference in lytic ability after 14/90 days or 1 year of cryopreservation ( F = 3.385, p = 0.125). Non-transduced T cells (NT) served as a negative control at an E/T ratio of 10:1.
    Chromium 51 ( 51 Cr) Release Method, supplied by srl inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/chromium+51+51+cr+release/chromium+51+++51+cr++release+method/pmc10780326-97-24-18
    Average 90 stars, based on 1 article reviews
    chromium-51 ( 51 cr) release method - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    chromium 51 51 cr release  (Revvity)
    91
    Revvity chromium 51 51 cr release
    <t>Chromium</t> <t>51</t> release assay for the evaluation of cytotoxicity of BCMA.CAR-T cells. A BCMA + U266 cell line or a BCMA − HL60 cell line were incubated for 4 h. The curves depict the specific lysis of target cells by BCMA.CAR-T cells at different E/T ratios ranging from 30:1 to 1:1. There was no significant difference in lytic ability after 14/90 days or 1 year of cryopreservation ( F = 3.385, p = 0.125). Non-transduced T cells (NT) served as a negative control at an E/T ratio of 10:1.
    Chromium 51 51 Cr Release, supplied by Revvity, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/chromium+51+51+cr+release/MicroBeta2+Microplate+Counters+for+Radiometric+and+Luminescence+Detection+with+6-detectors/pmc10663516-104-8-30
    Average 91 stars, based on 1 article reviews
    chromium 51 51 cr release - by Bioz Stars, 2026-09
    91/100 stars
    		  Buy from Supplier
    chromium cr 51 release assay  (Amersham Life Sciences Inc)
    90
    Amersham Life Sciences Inc chromium cr 51 release assay
    <t>Chromium</t> <t>51</t> release assay for the evaluation of cytotoxicity of BCMA.CAR-T cells. A BCMA + U266 cell line or a BCMA − HL60 cell line were incubated for 4 h. The curves depict the specific lysis of target cells by BCMA.CAR-T cells at different E/T ratios ranging from 30:1 to 1:1. There was no significant difference in lytic ability after 14/90 days or 1 year of cryopreservation ( F = 3.385, p = 0.125). Non-transduced T cells (NT) served as a negative control at an E/T ratio of 10:1.
    Chromium Cr 51 Release Assay, supplied by Amersham Life Sciences Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/chromium+51+51+cr+release/51cr/pm15001467-64-8-20
    Average 90 stars, based on 1 article reviews
    chromium cr 51 release assay - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Chromium 51 release assay for the evaluation of cytotoxicity of BCMA.CAR-T cells. A BCMA + U266 cell line or a BCMA − HL60 cell line were incubated for 4 h. The curves depict the specific lysis of target cells by BCMA.CAR-T cells at different E/T ratios ranging from 30:1 to 1:1. There was no significant difference in lytic ability after 14/90 days or 1 year of cryopreservation ( F = 3.385, p = 0.125). Non-transduced T cells (NT) served as a negative control at an E/T ratio of 10:1.

    Journal: International Journal of Molecular Sciences

    Article Title: In Vitro Functionality and Endurance of GMP-Compliant Point-of-Care BCMA.CAR-T Cells at Different Timepoints of Cryopreservation

    doi: 10.3390/ijms25031394

    Figure Lengend Snippet: Chromium 51 release assay for the evaluation of cytotoxicity of BCMA.CAR-T cells. A BCMA + U266 cell line or a BCMA − HL60 cell line were incubated for 4 h. The curves depict the specific lysis of target cells by BCMA.CAR-T cells at different E/T ratios ranging from 30:1 to 1:1. There was no significant difference in lytic ability after 14/90 days or 1 year of cryopreservation ( F = 3.385, p = 0.125). Non-transduced T cells (NT) served as a negative control at an E/T ratio of 10:1.

    Article Snippet: The cytotoxic efficiency of BCMA.CAR-T cells (effector cells, E) was assessed using a 4 h chromium-51 ( 51 Cr; Hartmann Analytic, Braunschweig, Germany) release assay.

    Techniques: Release Assay, Incubation, Lysis, Negative Control